Comirnaty provisionally approved for individuals 5 years and over in Australia

Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the COVID-19 vaccine Comirnaty for use in individuals five years and older, which will be marketed by the local subsidiary of US pharma giant Pfizer (NYSE: PFE).

This decision follows the provisional approvals granted by the TGA to Pfizer Australia for the use of Comirnaty in individuals 12 years and older on July 22, 2021 and the booster dose for use in adults 18 years and older on October 26, 2021.

Developed by Germany’s BioNTech (Nasdaq: BNTX) in partnership with Pfizer, Comirnaty has become the most prescribed vaccine against the coronavirus in the western world, generating direct sales of $13 billion in the third quarter of this year and with annual sales expected to top $36 billion.